Synta Announces Presentations at the 2013 Annual Meeting of the American Association of Cancer Research

LEXINGTON, Mass.–(BUSINESS WIRE)– Synta Pharmaceuticals Corp. (NAS: SNTA) announced today that poster presentations related to studies with ganetespib, a selective Hsp90 inhibitor in clinical development by the company, will be presented at the 2013 Annual Meeting of the American Association of Cancer Research in Washington, D.C. Presentations include:

Inhibition of mTOR enhances the activity of HSP90 inhibitors in part through cessation of heat shock protein synthesis

Presentation: Sunday, April 7, 1:00 – 5:00 PM ET
Abstract number: 1038
Authors: He, et al.

Ultra-deep sequencing of circulating free DNA to identify predictive, mutated HSP90 clients in the GALAXY Trial (NCT01348126): a randomized phase IIB/III study of ganetespib (STA-9090) in combination with docetaxel versus docetaxel alone in subjects with stage IIIb/IV NSCLC

Presentation: Monday, April 8, 1:00 – 5:00 PM ET
Abstract number: 2012
Authors: Fennell, et al.

The importance of dose schedule with HSP90 inhibitors: Results from a Phase II study in dogs with mast cell tumors

Presentation: Tuesday, April 9, 8:00 AM – 12:00 PM ET
Abstract number: 3369
Authors: London, et al.

Differential sensitivities to heat shock protein 90 (HSP90) inhibitors in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) cells

Presentation: Tuesday, April 9, 8:00 AM – 12:00 PM ET
Abstract number: 3272
Authors: Lee, et al.

Heat shock protein 90 functional inhibition regulates epithelial to mesenchymal transformation, invasion and migration via NF-kB and HIF-1α signaling in colorectal cancer

Presentation: Tuesday, April 9, 8:00 AM – 12:00 PM ET
Abstract number: 2707
Authors: Ganji, et al.

About Ganetespib

Ganetespib is an inhibitor of heat shock protein 90 (Hsp90) that is structurally unrelated to first-generation, ansamycin-related Hsp90 inhibitors. In preclinical experiments, ganetespib has shown activity in multiple tumor models …read more

Source: FULL ARTICLE at DailyFinance